1. Home
  2. FDMT

FDMT

4D Molecular Therapeutics Inc.

Logo 4D Molecular Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Founded: 2013 Country:
United States
United States
Employees: N/A City: EMERYVILLE
Market Cap: 1.3B IPO Year: 2020
Target Price: $42.44 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.58 EPS Growth: N/A
52 Week Low/High: $9.44 - $36.25 Next Earning Date: 05-08-2024
Revenue: $20,723,000 Revenue Growth: 562.29%
Revenue Growth (this year): -71.66% Revenue Growth (next year): 29.55%

Share on Social Networks: